This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NOVATO, Calif., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), today announced that Julie Anne Smith, executive vice president, strategy and chief operating officer of Raptor, will present an overview of the company at the Cowen and Company 33
rd Annual Health Care Conference in Boston at the Marriott Copley Place. Raptor's presentation will take place on Tuesday, March 5, 2013 beginning at 8:40 a.m. ET/5:40 a.m. PT.
A live audio webcast and archive of the presentation will be available on the company website at
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical is an emerging biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company is currently focused on the development of its first product candidate, RP103 (delayed-release oral cysteamine bitartrate), as a potential treatment for nephropathic cystinosis, a rare genetic disorder. In addition to cystinosis, the company is also testing RP103 for the potential treatment of non-alcoholic steatohepatitis, or NASH, a metabolic liver disorder, and Huntington's Disease, or HD, a neurodegenerative disorder.
For additional information, please visit
The Raptor Pharmaceutical Corp. logo is available at